Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $1.6 million.

  • Cyclerion Therapeutics' Net Cash Flow rose 19102.56% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 12720.56%. This contributed to the annual value of -$4.3 million for FY2024, which is 2553.7% up from last year.
  • Latest data reveals that Cyclerion Therapeutics reported Net Cash Flow of $1.6 million as of Q3 2025, which was up 19102.56% from -$633000.0 recorded in Q2 2025.
  • In the past 5 years, Cyclerion Therapeutics' Net Cash Flow ranged from a high of $25.1 million in Q2 2021 and a low of -$13.0 million during Q1 2021
  • Over the past 5 years, Cyclerion Therapeutics' median Net Cash Flow value was -$1.9 million (recorded in 2024), while the average stood at -$3.1 million.
  • Examining YoY changes over the last 5 years, Cyclerion Therapeutics' Net Cash Flow showed a top increase of 33649.63% in 2021 and a maximum decrease of 18552.37% in 2021.
  • Over the past 5 years, Cyclerion Therapeutics' Net Cash Flow (Quarter) stood at -$8.5 million in 2021, then grew by 17.72% to -$7.0 million in 2022, then skyrocketed by 78.08% to -$1.5 million in 2023, then surged by 123.36% to $360000.0 in 2024, then soared by 333.89% to $1.6 million in 2025.
  • Its Net Cash Flow was $1.6 million in Q3 2025, compared to -$633000.0 in Q2 2025 and $407000.0 in Q1 2025.